STANDARD OPERATING PROCEDURE

S01 – Preparation of Standard Operating Procedures in Research and Development

<table>
<thead>
<tr>
<th>Version</th>
<th>4.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective Date</td>
<td>24\textsuperscript{th} November 2017</td>
</tr>
<tr>
<td>Review Date</td>
<td>24\textsuperscript{th} November 2020</td>
</tr>
<tr>
<td>Author &amp; Position</td>
<td>Samantha Smart, Research Governance &amp; Quality Manager</td>
</tr>
<tr>
<td>Signature</td>
<td>[Signature]</td>
</tr>
<tr>
<td>Date</td>
<td>24/11/2017</td>
</tr>
<tr>
<td>Approver &amp; Position</td>
<td>Chris Gardner, R&amp;D Division Manager</td>
</tr>
<tr>
<td>Signature</td>
<td>[Signature]</td>
</tr>
<tr>
<td>Date</td>
<td>24/11/17</td>
</tr>
</tbody>
</table>

Controlled document
This document has been created following the Royal Devon and Exeter NHS Foundation Trust Policy for the Development, Ratification & Management of Procedural Documents. It should not be altered in any way without the express permission of the author or their representative.

It is the responsibility of all users of this SOP to ensure that the correct version is being used. If you are reading this in a paper format please refer to online to confirm you have the latest version.

DISCLAIMER
This generic R&D Standard Operating Procedure (SOP) must be followed unless a study specific SOP exists.

Once printed this is an uncontrolled document
## Full History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Author</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>25/02/2011</td>
<td>Research Manager and Governance Manager</td>
<td>New SOP</td>
</tr>
<tr>
<td>2.0</td>
<td>13/02/2014</td>
<td>Quality Assurance Coordinator</td>
<td>Document updated to reflect revised processes and procedures</td>
</tr>
<tr>
<td>3.0</td>
<td>12/09/2014</td>
<td>Quality Assurance Coordinator</td>
<td>Document updated to reflect revised processes and procedures</td>
</tr>
<tr>
<td>3.1</td>
<td>22/10/2015</td>
<td>Quality Assurance Coordinator</td>
<td>Updated reference number</td>
</tr>
<tr>
<td>3.2</td>
<td>22/09/2016</td>
<td>Quality Assurance Coordinator</td>
<td>Updated to reflect revised job titles and changes to hyperlinks</td>
</tr>
<tr>
<td>4.0</td>
<td>22/11/2017</td>
<td>Research Governance &amp; Quality Manager</td>
<td>Document updated to reflect revised processes and procedures; Revised into Trust template</td>
</tr>
</tbody>
</table>

### Associated Trust Policies/ Procedural documents:

- S04 Auditing processes in R&D
- S26 – Providing and Documenting Training for Researchers

### Key Words:

- R&D
- SOP
- Template
- Work Instruction

### In consultation with:

- Quality Assurance Group (September 2017)
- Divisional Governance Group (October 2017)
## Contents

1. INTRODUCTION  
2. PURPOSE  
3. SCOPE  
4. DEFINITIONS  
5. DUTIES AND RESPONSIBILITIES OF STAFF  
6. PROCEDURES  
   6.1 SOP layout and format  
   6.2 Creating a new SOP  
   6.3 Reviewing an SOP  
   6.4 Approval of SOPs  
   6.5 Distribution of SOPs  
   6.6 Training  
   6.7 SOP deviations  
   6.8 Withdrawing SOPs  
7. DISSEMINATION AND TRAINING FOR THIS DOCUMENT  
8. MONITORING COMPLIANCE AND EFFECTIVENESS OF THIS SOP  
9. ARCHIVING ARRANGEMENTS FOR THIS DOCUMENT  
10. REFERENCES
1. **INTRODUCTION**
   The purpose of a standard operating procedure (SOP) is to describe what needs to be done in order for a process to be conducted in compliance with the applicable standards and to ensure uniformity in the performance of a specific procedure. Research and Development (R&D) SOPs are designed to ensure that clinical research and its supporting activities are conducted to the principles of Good Clinical Practice (GCP) and the applicable regulations. Within R&D, SOPs are supported by Work Instructions (WIs) and other guidance documents which provide the detail on how to perform the specific task.

2. **PURPOSE**
   This document describes the procedure for preparing, approving and distributing SOPs.

3. **SCOPE**
   This SOP is applicable to all R&D staff who are involved in writing, reviewing, approving and implementing SOPs relating to Trust-wide systems and processes for research.

   For all research studies sponsored by R&D on behalf of the Trust, R&D SOPs will apply.

   For all research studies hosted by RDE, R&D SOPs should be considered the default procedures to be used except where study-specific procedures are specified in the protocol.

4. **DEFINITIONS**
   - CI: Chief Investigator
   - CTIMP: Clinical Trial of an Investigational Medicinal Product
   - CTU: Clinical Trials Unit
   - CTG: Clinical Trials Group
   - DGG: Divisional Governance Group
   - GCP: Good Clinical Practice
   - QA: Quality Assurance
   - R&D: Research & Development
   - SOP: Standard Operating Procedure
   - Sponsor: An individual, company, institution or organisation which takes responsibility for the initiation, management and financing of a clinical trial. Sponsorship activities may be delegated to the Investigator, CTU and/ or other organisations as appropriate
   - TMF: Trial Master File
   - WI: Work Instruction

5. **DUTIES AND RESPONSIBILITIES OF STAFF**
   The **Quality Assurance (QA) Group** will provide oversight of the SOP library, confirming the need for new procedural documents and those documents which need to be superseded or retired.

   The **QA Coordinator** is responsible for the day to day management of the SOP library to ensure that up to date versions of documents are made available, superseded versions are archived and to prompt document authors to undertake timely reviews.

   All **R&D personnel and research active staff** involved in writing, reviewing, approving and/ or implementing R&D SOPs must read and apply this document.
when writing or reviewing SOPs.

All R&D personnel and research active staff are responsible for ensuring that they have read, understood and documented training (if applicable) for all relevant SOPs.

All R&D personnel and research active staff have a responsibility to identify changes in policy, legislation and procedures that affect R&D SOPs and for bringing this to the attention of R&D.

6. PROCEDURES

6.1 SOP layout and format

6.1.1 All R&D SOPs must be written in the standard R&D SOP template. The SOP template is a controlled document and as such access is restricted to the QA Coordinator.

6.1.2 All R&D SOPs should contain the following sections as a minimum:
- Introduction
- Purpose
- Scope
- Definitions
- Duties and responsibilities of staff
- Procedures
- Dissemination and training
- Monitoring compliance and effectiveness
- Archiving
- References

Additional sections may be added.

6.2 Creating a new SOP

6.2.1 Where a member of staff or researcher identifies the need for a new SOP, a request should be made to the QA Group via the QA Coordinator. The QA Group will look to identify the most appropriate member(s) of staff to devise the new SOP and support the author in defining the scope of the SOP including supporting documentation such as WIs and/ or templates.

6.2.2 The QA Coordinator will provide the author with the current version of the R&D SOP Template.

6.2.3 New R&D SOPs shall be allocated an SOP number by the QA Coordinator.

6.2.4 SOPs must be written in a concise, step-by-step and clear format so that someone with limited experience or knowledge of the procedure, but with a basic understanding, can successfully carry out the procedure with limited supervision. Titles should be used rather than names.

6.2.5 SOPs will be called ‘Draft’ until they have been submitted for approval. The word ‘Draft’ must be watermarked on each page of the document and added to the document name in the footer.

6.2.6 Where applicable, any associated WIs, forms and templates should also be drafted/ updated and referenced within the SOP. Such documentation should not be developed independent of a supporting SOP (or protocol in the case of study-specific SOPs).

6.2.7 On completion of a draft SOP, internal review by appropriate staff members will be
undertaken. This review will consider readability, conciseness and accuracy of information. Any deficiencies should be addressed at this review stage.

6.2.8 The final draft SOP, together with any associated forms and templates should be sent to the QA Coordinator to coordinate review.

6.3 Reviewing an SOP

6.3.1 R&D SOPs will indicate on their front cover when they require a review. Each SOP will have an effective date (date of implementation following approval) and a review date which should be no more than three years from the effective date. The Author of the SOP is responsible for periodic review.

6.3.2 SOPs will also be reviewed on an ad hoc basis as a result of amendments to legislation, process or organisational change or following audit. It is the responsibility of any user to notify the R&D QA Coordinator if they believe an SOP needs reviewing before the review date.

6.3.3 R&D SOPs will be reviewed and agreed as described below. This may be done electronically or via a full meeting. Comments will be documented and addressed as required. Where necessary, other stakeholders will be consulted to guarantee that the SOP is workable in practice.

New SOPs
New SOPs relating to clinical aspects of research activity will be approved by the Associate Director for Clinical Trials (or Lead Nurse for Clinical Trials as deputy) on behalf of the Clinical Trials Group (CTG).

New SOPs relating to non-clinical aspects of research activity will be approved by the R&D Divisional Director (or Assistant R&D Manager or Research Governance & Quality Manager as deputy) on behalf of the R&D Divisional Governance Group (DGG).

Existing SOPs
Updates to existing SOPs will be reviewed by the QA Group to determine whether the changes made are minor or major as follows:

Minor changes constitute an amendment to the document that does not substantially affect the main body of the document (e.g. changes to references and standard forms) and will be reviewed and agreed by the document author and QA Group.

Major changes constitute an amendment to the document that will result in a change of practice and will be reviewed and agreed by the document author and either by the Associate Director for Clinical Trials (or Lead Nurse for Clinical Trials as deputy) on behalf of the CTG (clinical SOPs) or by the R&D Divisional Director (or Assistant R&D Manager or Research Governance & Quality Manager as deputy) on behalf of the R&D DGG (non-clinical SOPs).

6.4 Approval of SOPs

6.4.1 Once an R&D SOP has been satisfactorily reviewed and, if necessary, updated, it will be approved by the Associate Director for Clinical Trials (or Lead Nurse for Clinical Trials as deputy) on behalf of the CTG (clinical SOPs) or by the Divisional Governance Group (DGG) and approved by the R&D Divisional Director (or Assistant R&D Manager or Research Governance & Quality Manager as deputy) on behalf of the DGG and notified to the QA Coordinator.

6.4.2 The QA Coordinator shall prepare the SOP for publishing as follows:
- Each SOP will be issued with a unique reference number (using the format
R&D/SOP title/S#), an effective date and a review date.

- Each document associated with a SOP will be coded with the same reference number as the relevant SOP. So if the reference number of a SOP is R&D/Archiving of Essential Documents/S03, an associated work instruction would be R&D/Archiving of Essential Documents/WI03.

- The version history table on the front page of the SOP will be updated.

- References to draft versions will be removed from the watermark and footer.

- An electronic copy of the final SOP will be uploaded to the R&D Quality Management System.

- A master copy will be printed, signed by Author and by Approver and stored in the SOPs Master File in the office of the QA Coordinator.

- Copies of superseded SOPs will be destroyed and only the master copy will be retained electronically and archived to facilitate review by regulatory bodies (as required).

6.5 Distribution of SOPs
6.5.1 R&D SOPs will be uploaded to the Trust intranet as read-only documents. Where applicable, any associated templates and forms will be uploaded as separate documents for ease of use.

6.5.2 It is the responsibility of all staff to check the website regularly to see if SOPs have been added or amended. R&D will endeavour to notify research staff of any SOP developments that may be relevant to them via staff communications e.g. newsletters, Comms Cell.

6.5.3 A list of any new or updated SOPs will be provided to CTG and DGG at their regular meetings.

6.6 Training
6.6.1 Careful consideration must be given at study set up as to which SOPs will apply to a specific study. Full details must be included as a written statement in the study site file.

6.6.2 When a new SOP is authorised, or when an existing SOP is revised, self-directed training must be carried out by all staff to which the SOP is relevant and this training documented in their training record.

6.6.3 Staff should take time to read and fully understand the SOP and relevant documents, ensuring that they are able to implement the SOP when required. If clarification is needed, the staff member should approach R&D who will arrange additional training. All staff are responsible for maintaining their own training logs and copies must be made available to study monitors on request. See S26 – Providing and Documenting Training for Researchers for further information on training.

6.7 SOP deviations
6.7.1 If a process deviates from an approved SOP, a risk assessment should be undertaken to determine the consequences and identify any remedial action(s) that needs to be taken. It may also be appropriate to submit an incident report via the Datix system.

6.7.2 The author of the risk assessment must submit the risk assessment to the QA Group. Details may be escalated to DGG and/or CTG if appropriate.
6.8 **Withdrawing SOPs**
6.8.1 An SOP may be withdrawn if it describes a process that is obsolete. All withdrawn and/or superseded SOPs will be retained on the Quality Management System.
6.8.2 The QA Group will provide notification of a suspended or withdrawn document to staff members.

7. **DISSEMINATION AND TRAINING FOR THIS DOCUMENT**
7.1 This SOP and associated templates and forms will be uploaded to the Trust intranet and external website shortly after having been released.
7.2 All staff whose activities are subject to this SOP should ensure that they take time to read and understand the content of this SOP.

8. **MONITORING COMPLIANCE AND EFFECTIVENESS OF THIS SOP**
8.1 This SOP will be audited in line with [S04 Auditing processes in R&D](#).
8.2 Outcomes from audit will be presented to the R&D QA Group which will monitor any resulting action plans until all issues have been addressed to satisfaction.
8.3 Issues identified via the audit process which require escalation will be referred to the R&D Divisional Governance Group.

9. **ARCHIVING ARRANGEMENTS FOR THIS DOCUMENT**
9.1 The original of this document will remain with the R&D Quality Assurance Coordinator. An electronic copy will be maintained on the R&D section of the Q-Pulse document management system and a pdf copy on the Trust Intranet.
9.2 Archive copies must be maintained for any documents which have been superseded. Archive copies in electronic format should be retained indefinitely.

10. **REFERENCES**
ICH Guidelines for Good Clinical Practice (E6 (R2) Step 5. Dec 2016)